IsraelTuberculosis profile
Population  2017 8.3 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.015 (0.015–0.016) 0.18 (0.18–0.19)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.03 (0.02–0.04)
Incidence  (includes HIV+TB) 0.27 (0.23–0.31) 3.2 (2.8–3.7)
Incidence (HIV+TB only) 0.014 (<0.01–0.02) 0.17 (0.11–0.24)
Incidence (MDR/RR-TB)** 0.021 (<0.01–0.037) 0.25 (0.11–0.44)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.01 (<0.01–0.012) 0.085 (0.066–0.1) 0.095 (0.075–0.11)
Males 0.011 (<0.01–0.013) 0.16 (0.13–0.2) 0.17 (0.14–0.21)
Total 0.021 (0.017–0.024) 0.25 (0.21–0.29) 0.27 (0.23–0.31)
TB case notifications, 2017  
Total cases notified 234
Total new and relapse 234
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 100%
          - % pulmonary 73%
          - % bacteriologically confirmed among pulmonary 77%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.07 (0.06–0.08)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 12 5%
          - on antiretroviral therapy 10 83%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  12
(4–20)
Estimated % of TB cases with MDR/RR-TB 5.4% (2.2–11) 50% (1.3–99)  
% notified tested for rifampicin resistance 74% 29% 171
MDR/RR-TB cases tested for resistance to second-line drugs   8
Laboratory-confirmed cases MDR/RR-TB: 8, XDR-TB: 1
Patients started on treatment **** MDR/RR-TB: 8, XDR-TB: 1
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 79% 250
Previously treated cases, excluding relapse, registered in 2016 63% 8
HIV-positive TB cases registered in 2016 67% 18
MDR/RR-TB cases started on second-line treatment in 2015 80% 10
XDR-TB cases started on second-line treatment in 2015 100% 1
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2018  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-02-23 Data: www.who.int/tb/data